Zemcelpro® distribution agreement announced for Argentina, Hong Kong and Singapore

PartnershipZemcelproPositive

AI Analysis

Summary

FarmaMondo has been granted distribution rights for Zemcelpro (dorocubicel), a conditionally authorized cell therapy for hematological malignancies, in Argentina, Hong Kong, and Singapore.

Outcome Details

Distribution agreement granted for Argentina, Hong Kong and Singapore

Importance:5/10

Sentiment:

0.60

commercial_expansiondistribution_agreementeuropean_conditional_authorizationcell_therapy

Read the original article

Published by PR Newswire Clinical Trials on July 16, 2026 11:00 AM

Read Original